SANTA CLARA, Calif. / May 22, 2023 / Business Wire / Agilent Technologies Inc. (NYSE: A) today announced that the company will participate in Q&A sessions at the Jefferies and Goldman Sachs healthcare conferences. Below are details of each session.
Jefferies Global Healthcare Conference
Mike McMullen, Agilent President and CEO
Wednesday, June 7
9:00 – 9:25 a.m. ET / 6:00 – 6:25 a.m. PT
Goldman Sachs 44th Annual Global Healthcare Conference
Bob McMahon, Agilent CFO
Tuesday, June 13
1:00 – 1:40 p.m. ET / 10:00 – 10:40 a.m. PT
Those interested in listening to the live or recorded sessions can access them from the Events section of Agilent’s investor relations website. Recordings will be available for 90 days.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insight and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.85 billion in fiscal 2022 and employs 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.
Last Trade: | US$146.77 |
Daily Change: | -0.60 -0.41 |
Daily Volume: | 415,674 |
Market Cap: | US$43.010B |
January 30, 2024 January 16, 2024 December 04, 2023 |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB